JPMorgan Chase heads into the first week of June down nearly 2% on the week, with the stock at $300.96 — and the executive selling cadence that has defined this note for a month now showing no sign of reversal.
The insider story remains the defining signal here, even as the data continues to evolve. The most recent trades in the ORTEX dataset show the General Counsel selling 5,468 shares on May 20 at $300.27. Before that, five C-suite names — heads of asset management, commercial banking, technology, and consumer banking — each sold between 3,165 and 6,648 shares on May 15 at $298–$300. The CFO, COO, and Chief Risk Officer added to the cadence on May 5. The 90-day net across the executive group now runs to roughly $157 million in gross sales. ORTEX assigns these trades a significance score of 2, which reflects their small size relative to JPMorgan's scale — but the breadth and consistency of the pattern is the point. These are not isolated opportunistic sales. They have continued across multiple price levels, both into weakness and into recoveries.
The lending market tells a different story entirely, and the contrast is worth naming plainly. Short interest is barely present — just under 1% of the free float after a 6% rise over the week. Borrow availability is effectively unlimited: the ratio of shares available to lend relative to shares currently borrowed is so large it caps at the top of ORTEX's measurement range, and cost to borrow collapsed to just 0.09% on Tuesday — down nearly 59% over the week from already-low levels. This is a stock with no short-side pressure whatsoever. The two signals — executives consistently reducing exposure, short sellers completely uninterested — point in opposite directions, and that divergence is the central tension in the JPMorgan setup right now.
Options positioning has turned incrementally more cautious this week. The put/call ratio is running at 1.19, nearly 1.8 standard deviations above its 20-day average of 1.10. That's not an extreme — the 52-week high is 1.38 — but the direction is notable. The PCR has climbed steadily over the past two weeks from a mid-May low near 1.01, suggesting options traders have been adding downside protection as the stock pulled back from its May highs. Peer performance on the week was mixed: Wells Fargo and Citigroup both finished the week higher by roughly 2.5% and 3.5% respectively, while KeyCorp and Truist Financial each slipped around 1–3%. JPMorgan underperformed that peer group on the week, though it rebounded 1.5% on Tuesday.
The Street's view remains constructive, if not emphatic. The consensus stands at Buy, with a mean price target of $342 — roughly 14% above the current price. Analyst activity since mid-April has been uniformly upward on targets: Evercore ISI lifted its target to $340, Piper Sandler moved to $345, and even Hold-rated firms at Truist and Jefferies raised their numbers. The stock's ORTEX factor scores reflect an institution trading at fair value with strong earnings momentum — a 77th-percentile EPS surprise rank and a 77th-percentile forward EPS growth rank stand out, while 30-day EPS momentum has softened to the 37th percentile. The P/E at roughly 13x and price-to-book at 2.2x are undemanding for the franchise quality. Value has been slowly re-rating higher over the past 30 days even as the price slipped.
The next hard catalyst is the Q3 earnings release on July 14. The two most recent prints produced muted immediate reactions — a 0.4% gain in May and a 2.3% gain in April — before fading over the subsequent five days. What to watch between now and then: whether the executive selling continues at the current pace as the stock holds near $300, and whether options positioning escalates further toward the top of its 52-week range.
See the live data behind this article on ORTEX.
Open JPM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
